Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $20.25 Consensus Price Target from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned an average rating of “Hold” from the twenty-three analysts that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $20.25.

A number of research analysts have recently commented on NTLA shares. Canaccord Genuity Group dropped their price objective on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. JonesTrading upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Wednesday, March 4th. Wedbush reiterated a “neutral” rating and set a $12.00 target price on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Royal Bank Of Canada boosted their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 target price on Intellia Therapeutics in a report on Wednesday, January 28th.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $12.61 on Wednesday. Intellia Therapeutics has a 12 month low of $6.83 and a 12 month high of $28.25. The company has a 50-day moving average of $13.52 and a 200-day moving average of $11.94. The company has a market cap of $1.76 billion, a P/E ratio of -3.56 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The company had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. During the same quarter in the prior year, the company posted ($1.10) EPS. As a group, equities research analysts anticipate that Intellia Therapeutics will post -3.31 EPS for the current year.

Institutional Trading of Intellia Therapeutics

Institutional investors have recently modified their holdings of the company. Comerica Bank grew its holdings in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $33,000. Finally, Spire Wealth Management purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $37,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.